{"id":"NCT04417894","sponsor":"Regeneron Pharmaceuticals","briefTitle":"A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)","officialTitle":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-04-14","primaryCompletion":"2022-08-31","completion":"2022-11-23","firstPosted":"2020-06-05","resultsPosted":"2023-12-22","lastUpdate":"2023-12-22"},"enrollment":133,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Moderate to Severe Atopic Hand and Foot Dermatitis"],"interventions":[{"type":"DRUG","name":"dupilumab","otherNames":["DUPIXENTÂ®","REGN668","SAR231893"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"dupilumab","type":"EXPERIMENTAL"},{"label":"Matching Placebo","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to assess the efficacy of dupilumab on skin lesions in patients with atopic hand and foot dermatitis.\n\nThe secondary objectives of the study are:\n\n* To assess the efficacy of dupilumab on various other domains (pruritus, pain, sleep loss, health related QoL, work life impairment) in patients with atopic hand and foot dermatitis\n* To evaluate the safety and tolerability of dupilumab administered to patients with atopic hand and foot dermatitis\n* To evaluate systemic exposure and immunogenicity of dupilumab in patients with atopic hand and foot dermatitis","primaryOutcome":{"measure":"Percentage of Participants With Hand and Foot Investigator Global Assessment (IGA) 0 or 1 at Week 16","timeFrame":"At week 16","effectByArm":[{"arm":"Matching Placebo","deltaMin":16.7,"sd":null},{"arm":"Dupilumab Q2W","deltaMin":40.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"=0.0030"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":48,"countries":["United States","Germany","Japan","Poland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":66},"commonTop":["COVID-19","Nasopharyngitis","Dermatitis atopic","Upper respiratory tract infection","Blood creatine phosphokinase increased"]}}